能力验证计划中SARS-CoV-2的检出情况
美国能力验证研究所向346家临床实验室各发放2份样本,评估新开发的SARS-CoV-2检测方法的准确性。阳性样本含5,175病毒拷贝/mL,阴性样本含3,951病毒拷贝/mL的重组病毒颗粒。97.4%(302/310)的实验室正确检出病毒,98.3%(296/301)正确判定无病毒;错误结果中76.9%(10/13)可能与文书差错有关,占全部报告结果的1.6%(10/611)。
要点
- SARS-CoV-2 RNA检测能力验证总体表现优异,阳性检出正确率97.4%(302/310)。
- 阴性样本正确判定率98.3%(296/301)。
- 错误结果多与文书差错相关,占全部结果的1.6%(10/611)。
核心结论
- 该SARS-CoV-2 RNA检测能力验证总体表现优异,为新分子检测结果及基于其的临床和公共卫生决策提供了信心。
研究设计与样本
- 美国能力验证研究所向346家临床实验室各发放2份样本,评估SARS-CoV-2检测方法的准确性。
- 阳性样本含5,175病毒拷贝/mL,可完整提取SARS-CoV-2衣壳蛋白和RNA。
- 阴性样本含3,951病毒拷贝/mL的重组病毒颗粒,其序列靶向人RNAase P基因序列。
主要发现
- 97.4%(302/310)的实验室在病毒存在时正确检出。
- 98.3%(296/301)的实验室在病毒不存在时正确判定。
- 错误结果中76.9%(10/13)可能与文书差错有关,占全部报告结果的1.6%(10/611)。
临床怎么用
- 结果提示新开发的SARS-CoV-2分子检测方法总体准确,可支持临床与公共卫生决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: At the onset of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in the United States, testing was limited to the Centers for Disease Control and Prevention-developed reverse transcription polymerase chain reaction assay. The urgent and massive demand for testing prompted swift development of assays to detect SARS-CoV-2. The objective of this study was to assess the accuracy of these newly developed tests. METHODS: The American Proficiency Institute sent 2 test samples to 346 clinical laboratories in order to assess the accuracy of SARS-CoV-2 assays. The positive sample, containing 5,175 viral copies/mL, was fully extractable with SARS-CoV-2 viral capsid protein and RNA. The negative sample, with 3,951 viral copies/mL, contained recombinant virus particles with sequences for targeting human RNAase P gene sequences. RESULTS: Of the laboratories submitting results, 97.4% (302/310) correctly detected the virus when present and 98.3% (296/301) correctly indicated when the virus was not present. Among incorrect results reported in this proficiency challenge, 76.9% (10/13) were likely related to clerical error. This accounts for 1.6% (10/611) of all reported results. CONCLUSIONS: Overall performance in this SARS-CoV-2 RNA detection challenge was excellent, providing confidence in the results of these new molecular tests and assurance for the clinical and public health decisions based on these test results.
引用
- Edson DC, Casey DL, Harmer SE, et al. Identification of SARS-CoV-2 in a Proficiency Testing Program. Am J Clin Pathol. 2020. PMID: 32687172. doi:10.1093/ajcp/aqaa128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。